Jäger M, Hernigou P, Zilkens C, Herten M, Fischer J, Krauspe R
Orthopädische Klinik, Universitätsklinikum, Heinrich-Heine-Universität Düsseldorf, Moorenstrasse 5, 40225, Düsseldorf, Deutschland.
Orthopade. 2010 Apr;39(4):449-62; quiz 463. doi: 10.1007/s00132-009-1583-7.
In addition to stabilizing osteosynthesis and autologous bone transplantation, so-called orthobiologics are playing an increasing role in the treatment of bone-healing disorders. Besides the application of different growth factors, new data in the literature suggest that cell therapeutic agents promote local bone regeneration. Due to ethical and biological considerations, clinical application of progenitor cells for the musculoskeletal system is limited to autologous postpartum stem cells. Here in particular, cell therapy with autologous progenitor cells in one surgical session has delivered first promising results. Based on a review of the literature and on our own experience with 75 patients, this article reviews the rationale and characteristics of the clinical application of cell therapy for the treatment of bony substance defects. Most clinical trials report successful bone regeneration after the application of mixed cell populations from bone marrow.
除了稳定骨合成和自体骨移植外，所谓的骨生物制剂在骨愈合障碍的治疗中发挥着越来越重要的作用。除了应用不同的生长因子外，文献中的新数据表明细胞治疗剂可促进局部骨再生。出于伦理和生物学考虑，祖细胞在肌肉骨骼系统中的临床应用仅限于自体产后干细胞。特别是在这里，在一次手术中使用自体祖细胞进行细胞治疗已取得了初步的 promising 结果。基于文献综述和我们对75例患者的经验，本文回顾了细胞治疗在治疗骨质缺损中的临床应用原理和特点。大多数临床试验报告称，应用来自骨髓的混合细胞群体后骨再生成功。
